TY - GEN
T1 - Intraoperative beta- detecting probe for radio-guided surgery of brain tumors
AU - Baroni, Guido
AU - Bellini, Fabio
AU - Bocci, Valerio
AU - Collamati, Francesco
AU - Cremonesi, Marta
AU - De Lucia, Erika
AU - Faccini, Riccardo
AU - Ferroli, Paolo
AU - Fiore, S.
AU - Fioroni, Federica
AU - Grana, Chiara Maria
AU - Grassi, Elisa
AU - Iori, Mauro
AU - Marafini, Michela
AU - Mattei, Ilaria
AU - Morganti, Silvio
AU - Paganelli, Giovanni
AU - Patera, Vincenzo
AU - Pepe, Alessandra
AU - Piersanti, Luca
AU - Recchia, Luigi
AU - Russomando, Andrea
AU - Sarti, A.
AU - Sciubba, A.
AU - Schiariti, Marco Paolo
AU - Camillocci, E. Solfaroli
AU - Versari, Annibale
AU - Voena, Cecilia
PY - 2016/3/10
Y1 - 2016/3/10
N2 - The innovation of the radio-guided surgery exploiting β- emitters is the higher tumor-to-non-tumor ratio (TNR) allowing both a smaller radiopharmaceutical absorbed dose to detect cancerous remnants and the possibility of extending the technique also to cases with a large uptake of surrounding healthy organs, as for brain tumors. Our first study cases are meningiomas, since an appropriate β- emitting drug is already available (90Y-DOTATOC), but the goal is to apply this technique to gliomas. We verified the uptake of the radiotracer in 8/10 patients affected by meningiomas with TNR ≥ 10 and in 9/12 patients with a TNR ≥ 4 in case of gliomas. We developed prototypes of an intraoperative probe detecting β- radiation. The core of the probe is a millimetric scintillator made of para-terphenyl due to its high light yield and low density. Tests in laboratory showed that with a radiotracer activity on the tumor of 5 kBq/ml and a TNR of 10 a 0.1 ml cancerous residual can be detected in 1s. That corresponds to administer to the patient 1 MBq/kg of radiopharmaceutical, which is a dose comparable to those administered for diagnostic use. Finally we estimated with a detailed simulation the exposure of the surgeon resulted in ∼0.1 Sv/h to the whole body and ∼1 Sv/h to the hands, well below the corresponding values for established RGS with gamma radiation.
AB - The innovation of the radio-guided surgery exploiting β- emitters is the higher tumor-to-non-tumor ratio (TNR) allowing both a smaller radiopharmaceutical absorbed dose to detect cancerous remnants and the possibility of extending the technique also to cases with a large uptake of surrounding healthy organs, as for brain tumors. Our first study cases are meningiomas, since an appropriate β- emitting drug is already available (90Y-DOTATOC), but the goal is to apply this technique to gliomas. We verified the uptake of the radiotracer in 8/10 patients affected by meningiomas with TNR ≥ 10 and in 9/12 patients with a TNR ≥ 4 in case of gliomas. We developed prototypes of an intraoperative probe detecting β- radiation. The core of the probe is a millimetric scintillator made of para-terphenyl due to its high light yield and low density. Tests in laboratory showed that with a radiotracer activity on the tumor of 5 kBq/ml and a TNR of 10 a 0.1 ml cancerous residual can be detected in 1s. That corresponds to administer to the patient 1 MBq/kg of radiopharmaceutical, which is a dose comparable to those administered for diagnostic use. Finally we estimated with a detailed simulation the exposure of the surgeon resulted in ∼0.1 Sv/h to the whole body and ∼1 Sv/h to the hands, well below the corresponding values for established RGS with gamma radiation.
UR - http://www.scopus.com/inward/record.url?scp=84965082645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84965082645&partnerID=8YFLogxK
U2 - 10.1109/NSSMIC.2014.7430882
DO - 10.1109/NSSMIC.2014.7430882
M3 - Conference contribution
BT - 2014 IEEE Nuclear Science Symposium and Medical Imaging Conference, NSS/MIC 2014
ER -